Metagenomi Therapeutics, Inc. MGX 深 滬
等待開盤 08-21 09:30:00 美东时间
1.205
-0.035
-2.82%
華盛通- 最 高1.25
- 今 開1.21
- 成交量 7.95万股
- 最 低 1.20
- 昨 收 1.24
- 總市值 4552.14万
- 52周最高 3.95
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 1.13
- 委 比 88.49%
- 總股本 3777.71万
- 歷史最高 12.74
- 量 比 0.75
- 振 幅 4.03%
- 歷史最低 1.13
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
08-11 21:09
Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $(257.000 thousand...
08-11 04:26
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5
Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.
07-07 18:59
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.
05-12 21:27
Metagenomi Q1 EPS $(0.61) Misses $(0.55) Estimate, Sales $1.248M Miss $5.925M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 10.29 percent increase over losses of $(0.68) per share from the
05-12 04:23
Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication
04-16 19:04
Metagenomi Therapeutics Q4 Earnings Assessment
The earnings results for Metagenomi Therapeutics (NASDAQ:MGX) for Q4 were made ...
03-06 05:14
